Media

 
 
Larry Horn of MPEG LA to Present at NewYorkBIO 25th Anniversary Conference on May 5

(DENVER, CO, US – 4 May 2015) – MPEG LA, LLC today announced that President and CEO Larry Horn will speak at the NewYorkBIO 25th Anniversary Conference on May 5 in a session entitled "Strategic IP Management of Biomarker and Diagnostic Technologies" to be held at 10 on the Park at the Time Warner Center in New York City.

In pointing to the role MPEG LA’s licensing model has played in providing access, incentive, predictability and innovation around the market’s technology choices, Mr. Horn will discuss how changes in the legal environment surrounding intellectual property may have a negative, long-term impact on access and innovation critical to personalized medicine and other emerging technologies.


Full news release here

Diagnovus Becomes First Licensee to MPEG LA’s Librassay® Licensing Program

(DENVER, CO, US – 21 October 2013) – MPEG LA today announced that Diagnovus, LLC has entered into a license for certain patent rights through Librassay®, a new one-stop patent licensing program in the field of molecular diagnostics offered by patent licensing leader MPEG LA.

“We are pleased to welcome Diagnovus as a Licensee to the Librassay® program,” said Larry Horn, President and CEO of MPEG LA. “MPEG LA, through Librassay, provides a solution to the market’s growing need for one-stop non-exclusive access to patent rights for diagnostic tests that lead to personalized medical solutions. Just as MPEG LA’s origination of patent pools provided a market-based solution for accessing consumer electronics, video and information technologies, MPEG LA’s Librassay delivers a similar solution to the healthcare market with the potential for profound cost savings and quality of life benefits.”

“Librassay® is the answer to a growing market need for licenses under patents in support of emerging gene panel tests,” stated James Stover, Ph.D., Vice President of Business Development at Diagnovus. “When the patents are held by many different entities, securing licenses with each of them can be a challenge – especially for a small, fast moving company like Diagnovus. We welcome the convenience of Librassay’s efficient, cost-effective, one-stop licensing platform. By enabling us to access patent rights in a single transaction, Librassay allowed Diagnovus to quickly secure a license and add to our ENGAUGETM product line, saving valuable resources for what we do best – delivering personalized information and services to physicians treating patients suffering from underserved, aggressive and lesser-known diseases.”

“We welcome diagnostic developers and service providers, large and small, to visit the Librassay® website and contact us directly to lock in access to diagnostic patent rights held by a growing number of world-class research institutions,” added Kristin Neuman, Librassay Executive Director.

Launched in September 2012 (http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/83/n-12-09-27.pdf), Librassay® makes diagnostic patent rights from the world’s leading research institutions available to everyone through a single license. It also offers patent holders the opportunity for wider adoption of their technologies, reasonable compensation for their research investments and the incentive to invest more. The program currently includes some 400 patents owned by Johns Hopkins University; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); Partners HealthCare; The Board of Trustees of the Leland Stanford Junior University; The Trustees of the University of Pennsylvania; University of California, San Francisco; and Wisconsin Alumni Research Foundation (WARF)


Full news release here

MPEG LA Continues to Expand Librassay® with Addition of WARF

(DENVER, CO, US – 21 February 2013) – MPEG LA today announced that the Wisconsin Alumni Research Foundation (WARF) has become a participating patent holder in Librassay®, MPEG LA’s licensing supermarket of diagnostic and research tool patent rights for tests and assays, kits, tools and instruments for biomarker detection and analysis, diagnostics and research.

WARF joins leading research institutions Johns Hopkins University; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; National Institutes of Health (NIH); Partners HealthCare; The Board of Trustees of the Leland Stanford Junior University; The Trustees of the University of Pennsylvania; and University of California, San Francisco.

“The addition of WARF, with its rich history in technology transfer, makes the already impressive list of life sciences research institutions that have joined Librassay® even more distinguished,” said Larry Horn, MPEG LA President and CEO. “WARF’s decision to join Librassay® further validates the arrival of one- stop access to intellectual property rights that make diagnostic tests in support of personalized medical solutions available to everyone on the same terms.”

“We are pleased to announce the availability of UW-Madison technologies through Librassay® and its non-exclusive licensing model for many, which promotes social benefit and incentives for inventors and patent holders,” stated Leigh Cagan, WARF Chief Technology Commercialization Officer. “This licensing model is very helpful when patent rights held by many different parties are needed to develop licensing model is very helpful when patent rights held by many different parties are needed to develop new technologies, as often is the case with multiplexed diagnostic tests for disease and health conditions, including whole genome sequencing.”

Launched by one-stop patent licensing leader MPEG LA in September 2012 (see http://www.mpegla.com/Lists/MPEG%20LA%20News%20List/Attachments/83/n-12-09-27.pdf), Librassay® makes diagnostic patent rights from the world’s leading research institutions available to everyone through a single license. It also offers patent holders the opportunity for wider adoption of their technologies, reasonable compensation for their research investments and the incentive to invest more.

MPEG LA welcomes other patent holders to join Librassay®. For information, please email LicensorInfo-Librassay@mpegla.com.

To access the on-line Librassay® store, or request a copy of the Librassay® Patent Portfolio License, please go to www.librassay.com.


Full news release here

MPEG LA’s Librassay® Removes Patent Barriers to Diagnostics for Personalized Medicine
Collaboration with NIH and Other Leading Healthcare Innovators Provides One-Stop Access

(DENVER, CO, US – 27 September 2012) – MPEG LA announced today that Librassay®, a landmark collaboration with the National Institutes of Health (NIH) and other leading healthcare innovators (listed below), is now providing one-stop worldwide access to diagnostic discoveries for personalized medicine.

“Uncertainties surrounding access to patented technologies have imperiled healthcare advances,” said Larry Horn, MPEG LA President and CEO. “Just as MPEG LA’s origination of patent pools provided a market-based solution for accessing consumer electronics, video and information technologies, now MPEG LA’s Librassay® introduces a similar solution to the healthcare market with the potential for profound cost savings and quality of life benefits. We applaud the pioneering foresight and efforts of the world’s leading research institutions demonstrating a commitment to their understanding that making world class medical technology widely available is as important as inventing it.”

“The NIH’s policy is to disseminate its technologies as broadly as possible to promote commercialization and improve public health,” stated Mark Rohrbaugh, Director of the NIH Office of Technology Transfer. “This agreement promotes our policy by permitting MPEG LA and Librassay® to pool patented technologies contributed by NIH with complementary technologies from other sources, and to grant non-exclusive, commercial licenses from the pool for in vitro diagnostics and personalized medicine.”

“Before Librassay®, obtaining licenses to medical diagnostic inventions was an ordeal,” added Kristin Neuman, Librassay® Executive Director. “Now Librassay® offers one place where diagnostic developers and service providers can obtain assured and affordable access to patent rights, and patent holders have the opportunity for wider adoption of their technologies in combination with others, reasonable compensation for their research investments and the incentive to invest more.”

Initial contributors to Librassay® include

  • Johns Hopkins University
  • Ludwig Institute for Cancer Research
  • Memorial Sloan-Kettering Cancer Center
  • National Institutes of Health
  • Partners HealthCare
  • The Board of Trustees of the Leland Stanford Junior University
  • The Trustees of the University of Pennsylvania
  • University of California, San Francisco

Starting with some 400 patents, Librassay® makes worldwide medical diagnostic patent rights from the world’s leading research institutions available to everyone through a one-stop license. Librassay® is expected to be of particular benefit in connection with emerging multiplexed diagnostic tests for disease and other health conditions, including whole genome sequencing, for which patent rights belonging to many different parties may be needed.

MPEG LA welcomes other patent holders to join Librassay®. For information, please email LicensorInfo-Librassay@mpegla.com.

To access the on-line Librassay® store, or request a copy of the Librassay® Patent Portfolio License, please go to www.librassay.com.


Full news release here

MPEG LA's Librassay® Featured in Genetic Diagnostic Testing Testimony at USPTO

(DENVER, CO, US – 16 February 2012) – MPEG LA, LLC, world leader in alternative one-stop patent licenses, testified today at a public hearing on Genetic Diagnostic Testing at the US Patent and Trademark Office to introduce Librassay®, a market-based solution addressing genetic diagnostic patent licensing issues of concern to the panel. Through a patent licensing “supermarket” making essential patent rights available on a nonexclusive, nondiscriminatory basis, Librassay® will accelerate adoption and availability of genetic diagnostic tests leading to personalized medical solutions in service to the entire market.


Full news release here

MPEG LA Launches Initiative to Make Gene Patents Available for Diagnostic Testing
Licensing Facility Balances Open Access with Innovation to Deliver Diagnosis and Treatment

(DENVER, CO, US – 8 April 2010) – MPEG LA, LLC, world leader in alternative one-stop patent licenses, today announced a market-based initiative for a diagnostic genetics patent licensing facility that addresses the market’s need for nonexclusive access to patents for diagnostic genetics tests leading to personalized medical solutions that save lives and reduce healthcare costs.

“Diagnostic genetics testing holds great promise as a driver of precision therapy, but patent thickets and restrictive licensing arrangements threaten their delivery,” said MPEG LA President and CEO Larry Horn. “The recent case of Association for Molecular Pathology vs. USPTO, Myriad Genetics and University of Utah Research Foundation (US District Court for the Southern District of New York) suggests the need for a solution that balances social cost and open access with innovation incentive. Applying its leading mass market patent licensing expertise in service to the healthcare market, MPEG LA is prepared to deliver it. We welcome all owners of relevant patents to join those who have expressed their support for this effort.”


Full news release here